Management of MASH Cirrhosis

Introduction to MASH Cirrhosis Management

The American Gastroenterological Association recommends that patients with MASH cirrhosis require hepatology-coordinated multidisciplinary care focused on preventing decompensation, hepatocellular carcinoma surveillance every 6 months with ultrasound, variceal screening, and aggressive management of metabolic comorbidities while avoiding hepatotoxic medications 1, 2

The American Association for the Study of Liver Diseases suggests that all patients with confirmed MASH cirrhosis must undergo hepatocellular carcinoma (HCC) surveillance with right upper quadrant ultrasound every 6 months, as 2-3% of MASH cirrhosis patients develop HCC annually 3, 2
The American College of Gastroenterology recommends esophagogastroduodenoscopy (EGD) screening for esophageal varices at diagnosis, with repeat screening based on findings 3, 2
The Mayo Clinic suggests referral to transplant center evaluation when appropriate for decompensation risk assessment 3, 2
Laboratory monitoring every 6 months is recommended, including complete blood count, liver panel, INR, creatinine, and albumin 3, 2

The American Heart Association recommends targeting 7-10% weight loss through structured programs, as this improves steatohepatitis and potentially reverses fibrosis even in cirrhotic patients 1, 4
A Mediterranean diet daily, including vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil, is suggested 1, 4
Limiting simple sugars, red meat, processed meats, and ultra-processed foods is recommended 1, 4
Engaging in 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity exercise weekly is advised 1, 5

The European Association for the Study of the Liver states that vitamin E (800 IU/day) may be considered based on retrospective data showing improved transplant-free survival and lower hepatic decompensation rates in NASH patients with advanced fibrosis or cirrhosis 1, 5
Pioglitazone is contraindicated in decompensated cirrhosis but may be used cautiously in compensated cirrhosis, though evidence is limited 7
GLP-1 receptor agonists (semaglutide, liraglutide) appear safe overall but have not been widely tested in cirrhotic patients 7

The American Diabetes Association prefers GLP-1 receptor agonists when diabetes control is needed, given their potential liver benefits 1, 7, 5
SGLT2 inhibitors reduce steatosis by approximately 20% and provide cardiovascular and renal benefits 7
Pioglitazone improves liver histology but causes weight gain and is contraindicated in decompensated cirrhosis 1, 7, 5
Statins are safe and strongly recommended in Child A or B cirrhosis, reducing hepatic decompensation by 46% and mortality by 46% in meta-analyses 7, 9

The American Association for the Study of Liver Diseases recommends right upper quadrant ultrasound every 6 months for all cirrhotic patients 3, 2, 6
Alpha-fetoprotein (AFP) may be added to ultrasound surveillance 6
Screening for varices with EGD at cirrhosis diagnosis is suggested 3, 2
Screening for varices if liver stiffness ≥20 kPa or thrombocytopenia present is recommended 4, 10

The American Gastroenterological Association states that bariatric surgery is NOT contraindicated in compensated MASH cirrhosis but requires careful patient selection 9
Foregut bariatric surgery improves or resolves steatosis, steatohepatitis, and fibrosis in most patients 9

The American Association for the Study of Liver Diseases suggests referring to transplant center when decompensation occurs or when meeting standard transplant criteria 3, 2

The American Heart Association advises not to neglect cardiovascular risk assessment, as cardiovascular disease drives mortality before cirrhosis develops 4
The European Association for the Study of the Liver recommends not to use pioglitazone in decompensated cirrhosis despite its efficacy in earlier disease stages 7
The American College of Cardiology suggests not to assume statins are contraindicated—they are safe and beneficial in compensated cirrhosis (Child A-B) 7, 9
The American Association for the Study of Liver Diseases advises not to overlook HCC surveillance—MASH cirrhosis carries 2-3% annual HCC incidence 3, 2
The American Gastroenterological Association recommends not to permit any alcohol consumption, even in small amounts 4, 6